Visualize HL7 Example and Test Instances (vi7eti)

Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/

Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.

BACK TO LIST

Patient
Name:	Χιτός, Νταίζη
DOB:	18-APR-1966 (Age: 59)
Gender:	female
ID:	3548-787769-4 (ECI)

Author
Dr. Ping, Hel

Patient summary Document
European Patient Summary
Report Date:	26-AUG-2024

Problem list

Condition	Onset Date	Status
Harmful pattern of use of opioid	12-Jan-2015	active
Transformed migraine	05-Feb-2014	active
Idiopathic atrophic hypothyroidism	26-Aug-2012	active
Essential hypertension	22-Mar-1999	active
Prediabetes	15-Mar-1993	active
Anemia	15-Mar-1993	active

Medication list

No known medications

Immunizations list

Vaccine	Date
Influenza virus antigen only vaccine product	26-Aug-2024
Clostridium tetani toxoid antigen adsorbed only vaccine product	21-Aug-2023
SARS-CoV-2 mRNA vaccine	19-Apr-2021

Allergies and Intolerances

Allergy/Intolerance	Onset Date	Status	Type	Reaction
Vaccine product containing SARS-CoV-2 mRNA	?	active	?

Care Plan

Active Planned Care / Goals	Start Date	Reason
Therapy	21-Mar-2014	-
Musculoskeletal care	05-Aug-2011	Localized primary osteoarthritis of the hand
Decrease hand pain severity to improve function and quality of life. Increase ability to perform daily activities requiring hand use. Decrease swelling in affected hand joints.
Lifestyle education regarding hypertension	22-Mar-1999	Essential hypertension (disorder)
Patient will demonstrate understanding and begin implementing recommended lifestyle changes (diet, exercise, sodium reduction, weight management) to help control blood pressure.
Diabetes self management plan	15-Mar-1993	Prediabetes
Achieve and maintain Hemoglobin A1c below 5.7% through diabetes self-management strategies. Achieve and maintain a weight loss of at least 5% of baseline body weight to reduce risk of progression to diabetes. Maintain systolic blood pressure below 130 mmHg and diastolic blood pressure below 80 mmHg.

Vital Signs

Vital Signs	2024-08-26	2023-08-21
Body Height	163.2 cm	163.2 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported	1 {score}	1 {score}
Body Weight	73.4 kg	73.4 kg
Body mass index (BMI) [Ratio]	27.6 kg/m2	27.6 kg/m2
Diastolic Blood Pressure	66 mm[Hg]	65 mm[Hg]
Systolic Blood Pressure	104 mm[Hg]	106 mm[Hg]
Heart rate	95 /min	88 /min
Respiratory rate	13 /min	14 /min

Relevant diagnostic tests/laboratory data

Recent Lab Observations	26-AUG-2024	Reference Range	Unit
Hemoglobin A1c/Hemoglobin.total in Blood	6.2	4.3 - 6.4	%
Glucose [Mass/volume] in Blood	90.7	70 - 140	mg/dL
Urea nitrogen [Mass/volume] in Blood	16.7	7 - 20	mg/dL
Creatinine [Mass/volume] in Blood	0.7	0.5 - 1.1	mg/dL
Calcium [Mass/volume] in Blood	8.7	8.5 - 10.5	mg/dL
Sodium [Moles/volume] in Blood	143.3	135 - 145	mmol/L
Potassium [Moles/volume] in Blood	5.0	3.5 - 5.1	mmol/L
Chloride [Moles/volume] in Blood	107.0	98 - 110	mmol/L
Carbon dioxide, total [Moles/volume] in Blood	20.3 L	22 - 29	mmol/L

Device Use

Device	Date (since)
Blood glucose meter (physical object)	15-Mar-1993